Intellia Therapeutics (38I) AI Stock Analysis

Company Guidance

Intellia said it expects FDA acceptance of the lonvo‑z BLA by year‑end and is preparing for a potential U.S. launch in H1 2027 (pre‑commercial hires complete); it reported $628.4M cash, cash equivalents and marketable securities as of June 30, 2026 (after ~ $195M net equity financing in April) and believes this funding should carry the company at least into 2028 (conservative, excludes product revenue); Q2 metrics included collaboration revenue $7.7M, R&D $82.6M (stock‑comp $9.4M), G&A $37.8M (stock‑comp $8.6M) and net loss $106.6M; clinical guidance highlighted HAELO topline that showed an 87% reduction in mean monthly attacks vs placebo, 62% of patients attack‑ and therapy‑free, and a 23‑point improvement in angioedema QoL over 6 months (vs a 6‑point meaningful change), while nex‑z dosing resumed in Q2, MAGNITUDE has enrolled >650 patients with a blinded event rate within internal projections and MAGNITUDE‑2 enrollment expected to complete later this year; safety work sequenced >600 samples, found HLA C*05:01 in ~12% of patients and linked it to the highest transaminase elevations (Grade 4 events <1% overall), prompting HLA typing and mitigation measures across ongoing trials, and Phase I nex‑z showed ~90% mean TTR reduction with mean serum TTR <20 µg/mL within 1 month.